CatSci, a UK-based process research and development contract research organization, announced the appointment of Paul Bradley as its new head of business development. Bradley joins the team with nearly 3 decades of experience in drug discovery and development, covering both scientific and commercial roles. He previously held senior positions with Pfizer, Charnwood Molecular and Concept Life Sciences.

Ross Burn, CEO of CatSci, commented: "We are thrilled that Paul has chosen to join our team. Both his technical and commercial knowledge are synergistic with our strategy to continue to grow the business by delivering customized chemistry solutions for drug discovery and development."

Simon Tyler, the company’s COO, added: "Paul’s recruitment is a milestone in the emergence of CatSci as a premier service provider to innovator pharma, and will further enhance our business performance. Throughout his career, Paul has demonstrated success in both delivering drug development programs and accelerating commercial growth. His technical expertise and commercial experience will undoubtedly be a great asset as we seek to serve our customers’ chemistry needs from late-stage lead optimization all the way through to product launch."